ArticleScientific reports2013
Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin.
Article in Scientific reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04293887 (Randomized, Open, Blank Control Study on the Efficacy and Safety of Recombinant Human Interferon α1β in the Treatment of Patients With New Type of Coronavirus Infection in Wuhan), which is not on this map. Cited by 194 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized, Open, Blank Control Study on the Efficacy and Safety of Recombinant Human Interferon α1β in the Treatment of Patients With New Type of Coronavirus Infection in Wuhan
Who cites it
194 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review ofTheranostics · 2021Pooled it
- Evaluation of safety, efficacy, tolerability, and treatment-related outcomes of type I interferons for human coronaviruses (HCoVs) infection in clinical practice: An updated critical systematic review and meta-analysis.International immunopharmacology · 2020Pooled it
- Pharmacologic Treatments and Supportive Care for Middle East Respiratory Syndrome.Emerging infectious diseases · 2020Pooled it
- Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19).Intensive care medicine · 2020Guideline
- Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta-analysis.Reviews in medical virology · 2018Pooled it
- A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV).Travel medicine and infectious diseasePooled it
- Computational Discovery of MERS-CoV Main Protease Inhibitors Through Screening and Molecular Dynamics Simulations.Proteins · 2026Article
- Harnessing the power of IFN for therapeutic approaches to COVID-19.Journal of virology · 2024Review
- AnHeliyon · 2024Article
- Therapeutic Management with Repurposing Approaches: A Mystery During COVID-19 Outbreak.Current molecular medicine · 2024Review
- Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial.EClinicalMedicine · 2023Article
- Ribavirin aerosol in hospitalized adults with respiratory distress and COVID-19: An open-label trial.Clinical and translational science · 2023Article
- A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.Narra J · 2022Review
- Comparative overview of emerging RNA viruses: Epidemiology, pathogenesis, diagnosis and current treatment.Annals of medicine and surgery (2012) · 2022Review
- RdRp inhibitors and COVID-19: Is molnupiravir a good option?Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Review
- Strategies for drug repurposing against coronavirus targets.Current research in pharmacology and drug discovery · 2022Review
- Cardiovascular implications of the COVID-19: Management of complications and drug safety concerns.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2022Review
- Prediction of Omicron Virus Using Combined Extended Convolutional and Recurrent Neural Networks Technique on CT-Scan Images.Interdisciplinary perspectives on infectious diseases · 2022Article
- The role of type I interferon in the treatment of COVID-19.Journal of medical virology · 2022Review
134 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The identification of a novel β coronavirus, nCoV, as the causative agent of severe respiratory illness in humans originating in Saudi Arabia, Qatar and Jordan has raised concerns about the possibility of a coronavirus pandemic similar to that of SARS-CoV. As a definitive treatment regimen has never been thoroughly evaluated for coronavirus infections, there is an urgent need to rapidly identify potential therapeutics to address future cases of nCoV. To determine an intervention strategy, the effect of interferon-α2b and ribavirin on nCoV isolate hCoV-EMC/2012 replication in Vero and LLC-MK2 cells was evaluated. hCoV-EMC/2012 was sensitive to both interferon-α2b and ribavirin alone in Vero and LLC-MK2 cells, but only at relatively high concentrations; however, when combined, lower concentrations of interferon-α2b and ribavirin achieved comparable endpoints. Thus, a combination of interferon-α2b and ribavirin, which are already commonly used in the clinic, may be useful for patient management in the event of future nCoV infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.